[EN] COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE [FR] COMPOSÉS EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C (VHC) ET LEURS UTILISATIONS EN MÉDECINE
[EN] SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] ACIDES SUBSTITUES POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
申请人:ASTRAZENECA AB
公开号:WO2006005909A1
公开(公告)日:2006-01-19
The invention relates to substituted acids of formula (I), where T,W,X,Y,Z,R1 and R2 as defined in the claims, as useful pharmaceutical compounds for treating asthma and rhinitis, pharmaceutical compositions containing them, and a processes for their preparation.
Substituted Acids for the Treatment of Respiratory Diseases
申请人:Bonnert Victor Roger
公开号:US20080114002A1
公开(公告)日:2008-05-15
The invention relates to substituted acids of formula (I), where T, W, X, Y, Z, R
1
and R
2
as defined in the claims, as useful pharmaceutical compounds for treating asthma and rhinitis, pharmaceutical compositions containing them, and a processes for their preparation.
Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma
申请人:Hemmerling Martin
公开号:US20100081692A1
公开(公告)日:2010-04-01
The invention provides 1-benzyl-4-piperidinamines of the general formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma. The compounds are inhibitors of the CCR1 receptor.
Substituted acids for the treatment of respiratory diseases
申请人:AstraZeneca AB
公开号:US08022248B2
公开(公告)日:2011-09-20
The invention relates to substituted acids of formula (I), where T, W, X, Y, Z, R1 and R2 as defined in the claims, as useful pharmaceutical compounds for treating asthma and rhinitis, pharmaceutical compositions containing them, and a processes for their preparation.
Ligand-Enabled C–H Hydroxylation with Aqueous H<sub>2</sub>O<sub>2</sub> at Room Temperature
作者:Zhen Li、Han Seul Park、Jennifer X. Qiao、Kap-Sun Yeung、Jin-Quan Yu
DOI:10.1021/jacs.2c08332
日期:2022.10.5
carboxyl-pyridone (CarboxPyridone) ligand that enables room-temperature Pd-catalyzed C–H hydroxylation of a broad range of benzoic and phenylacetic acids with an industry-compatible oxidant, aqueous hydrogenperoxide (35% H2O2). The scalability of this methodology is demonstrated by a 1000 mmol scale reaction of ibuprofen (206 g) using only a 1 mol % Pd catalyst loading. The utility of this protocol is further
随着过去十年中大量Pd(II)催化的天然底物C-H活化反应的发展,开发能够在安全实用的条件下使用绿色氧化剂的催化剂已成为一个日益重要的挑战。值得注意的是,Pd(II) 催化剂与可持续含水 H 2 O 2的相容性一直是包括瓦克型氧化在内的催化领域的长期挑战。我们在此报道了一种双功能双齿羧基吡啶酮 (CarboxPyridone) 配体,该配体能够使用工业兼容的氧化剂过氧化氢水溶液 (35% H 2 O)在室温下 Pd 催化的各种苯甲酸和苯乙酸的 C-H 羟基化反应。2)。仅使用 1 mol% Pd 催化剂负载的布洛芬 (206 g) 的 1000 mmol 规模反应证明了该方法的可扩展性。通过产品的衍生化以及从使用该方法制备的苯酚中间体合成多氟天然产物古美斯坦和紫檀烯,进一步说明了该协议的实用性。